Peter MacCallum Cancer Centre, education and treatment center and Isotopia Molecular Imaging Limited (Isotopia), a global supplier of radioisotopes for targeted therapies, recently announced they have signed a clinical research and supply agreement for the medical radioisotope no-carrier-added Terbium-161 (n.c.a. Tb-161), an innovative therapeutic isotope used for targeted cancer treatment, which also allows imaging and hence use in ‘Theranostics’, the emerging concept for personalized therapy. 

As part of this agreement, Isotopia will supply ¹⁶¹Tb to support a first-in-human pilot study conducted by the Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) at Peter Mac.

To read more please visit:

Isotopia and the Peter MacCallum Cancer Center announce Terbium-161 clinical study collaboration

Source: ISOTOPIA